Tolvaptan (JINARC®) is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with CKD stage 1 to 4 at initiation of treatment with evidence of rapidly progressing disease (see Pharmacology: Pharmacodynamics under Actions).
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
